Live Breaking News & Updates on Ncluding Nuvaxovid

Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We are pleased to collaborate with SK b ....

South Korea , United States , Giovanna Chandler , Jaeyong Ahn , Erika Schultz , Stanleyc Erck , Korean Ministry Of Food , Drug Administration , Prnewswire Novavax Inc , Exchange Commission , Administration Of Nuvaxovid , European Union , Serum Institute Of India , Novavax Inc , Post Approval Change Application , Korean Ministry , Drug Safety , Chief Executive Officer , Name Use , Product Characteristics , Package Leaflet , Prescribing Information , Important Safety Information , Serum Institute , Vaccine Efficacy Novavax Trial , New England Journal ,